Table 3.
The average change in tumor board presentation rate per tumor entity and year from 2014 to 2020, January 2019 to October 2019 (pre-COVID-19 pandemic) vs. January 2020 to October 2020 (during COVID-19 pandemic) and during the shutdown period from March 2020 to May 2020 compared with March 2019 to May 2019.
| Tumor entity | Average change/year | 01-10/2019 | 01-10/2020 | Change 2020 vs. 2019 | Average change from |
|---|---|---|---|---|---|
| 2014–2020 | March to May 2020 | ||||
| [%, (95% CI)]* | vs. 2019* | ||||
| N | N | N [% (95% CI)] | N [% (95% CI)] | ||
| Biliary tract (gall bladder, extrahepatic bile duct, ampulla vateri) | +8.1% (1.3, 15.3) | 110 | 92 | −18 [−16.4% (−36.5, 10.3)] | −26 [−50% (−69.9, −15.0)] |
| Esophagus | +4.5% (1.0, 8.0) | 220 | 194 | −26 [−11.8% (−27.3, 7.0)] | −10 [−15.2% (−40.4, 21.1)] |
| Colon | +5.1% (1.3, 9.0) | 337 | 305 | −32 [−9.5% (−22.5, 5.7)] | −5 [−5.1% (−28.5, 26.0)] |
| Pancreas | +10% (5.7, 14.6) | 327 | 300 | −27 [−8.3% (−21.5, 7.3)] | −29 [−17.6% (−37.6, 9.1)] |
| Rectum | +4.1% (1.2, 7.1) | 374 | 358 | −16 [−4.3% (−17.2, 10.6)] | −4 [−3.9% (−27.0, 26.6)] |
| Liver (HCC and intrahepatic bile duct) | +6.0% (1.7, 10.4) | 247 | 242 | −5 [−2.0% (−17.9, 17.0)] | −12 [−13.5% (−32.6, 11.0)] |
| Stomach (incl. esophagogastric junction) | +2.9% (0.1, 5.8) | 211 | 247 | +36 [+17.0% (−2.6, 40.6)] | +6 [+8.8% (−21.7, 51.0)] |
*
Time series analysis with a linear trend.